Dexmedetomidine and haloperidol in reducing symptoms of delirium

Comparison of the efficacy and adverse effects of dexmedetomidine and haloperidol in reducing thesymptoms of Deliriumin patients in Intensive Care Unit of khorshid hospital in Isfahan in 2022 - ARandomized Clinical Trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241224064155N1

Enrollment

Registered

2025-03-02

Start date

2022-11-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium. Delirium due to known physiological condition

Interventions

Intervention 1: Intervention group: Injecting dexmedetomidine, manufactured by Abu Raihan Company, as an intravenous injection at a dose of 0.5 micrograms/kg per hour. Intervention 2: Control group: I

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: Informed consent Definite delirium diagnosis

Exclusion criteria

Exclusion criteria: Opium analgesic treatment

Design outcomes

Primary

Measure	Time frame
Delirium treatment. Timepoint: Every 6 hours for up to 3 days. Method of measurement: RAAS questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmadreza aghabozorgi

Esfahan University of Medical Sciences

Aghabozorgi.ahmadreza@gmail.com+98 31 3668 7898

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026